A high-throughput screen for TMPRSS2 expression identifies FDA-approved compounds that can limit SARS-CoV-2 entry

A high-throughput screen for TMPRSS2 expression identifies FDA-approved compounds that can limit SARS-CoV-2 entry

The serine protease TMPRSS2 primes SARS-CoV-2 glycoprotein for cell entry. Here, the authors perform a screen to identify drugs that reduce TMPRSS2 expression and find that halofuginone modulates proteasome-mediated degradation of TMPRSS2 and reduces entry of SARS-CoV-2.

Guardado en:
Detalles Bibliográficos
Autores principales: Yanwen Chen, Travis B. Lear, John W. Evankovich, Mads B. Larsen, Bo Lin, Irene Alfaras, Jason R. Kennerdell, Laura Salminen, Daniel P. Camarco, Karina C. Lockwood, Ferhan Tuncer, Jie Liu, Michael M. Myerburg, John F. McDyer, Yuan Liu, Toren Finkel, Bill B. Chen
Formato: article
Lenguaje:EN
Publicado: Nature Portfolio 2021
Materias:
Science
Q
Acceso en línea:https://doaj.org/article/a96a0ab6494b4682a6b6f2fb49128893
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
Descripción
Sumario:The serine protease TMPRSS2 primes SARS-CoV-2 glycoprotein for cell entry. Here, the authors perform a screen to identify drugs that reduce TMPRSS2 expression and find that halofuginone modulates proteasome-mediated degradation of TMPRSS2 and reduces entry of SARS-CoV-2.

Ejemplares similares